EQUES Awarded Contract for AI Platform Verification Project for AMED
EQUES Co., Ltd., an AI startup from the University of Tokyo's Matsuo Lab, announced it has been awarded a contract and has begun a project for the Japan Agency for Medical Research and Development (AMED). The contract, won through a public tender, is for the "Trial Construction and Consulting Services for a Generative AI System for Drug Discovery Support." This trial project aims to improve operational efficiency and enhance Japan's drug discovery capabilities by leveraging AMED's accumulated drug discovery knowledge. The project will verify the applicability of generative AI, identify technical and operational challenges, and confirm compliance with security and governance standards.
📋 Article Processing Timeline
- 📰 Published: May 19, 2026 at 19:00
- 🔍 Collected: May 19, 2026 at 10:31
- 🤖 AI Analyzed: May 20, 2026 at 06:52 (20h 20m after Collected)
EQUES Co., Ltd., an AI startup originating from the Matsuo Lab at the University of Tokyo, has announced that it was awarded a contract for a verification project (trial project) concerning an AI platform for internal use at the Japan Agency for Medical Research and Development (AMED). The contract is for the "Trial Construction and Consulting Services for a Generative AI System for Drug Discovery Support," a public tender conducted by AMED, and the project has now commenced.
In recent years, as interest in the use of digital technology in government agencies has grown, careful consideration is being given to the application of AI for improving operational efficiency and supporting decision-making, while addressing security and operational challenges. AMED has also been planning a phased examination of the potential for AI use in its internal operations.
This project is part of an initiative to enhance the operational efficiency of "Exit-oriented R&D Management," as stated in AMED's 3rd Mid-to-long-term Plan. The goal is to contribute to strengthening Japan's drug discovery capabilities by using generative AI to effectively utilize the drug discovery knowledge and project information accumulated within AMED, thereby accelerating the commercialization of promising drug discovery seeds.
The project will be conducted as a trial to perform technical and operational verification prior to a full-scale implementation of the AI platform. Through limited and non-public trial operations using AMED's accumulated drug discovery knowledge and project information, the following aspects will be verified:
- Assessment of the applicability of generative AI technology.
- Identification of technical and operational challenges for internal use.
- Confirmation of compliance with security and governance.
This initiative is in the verification phase, and the content of its results and future developments are not determined at this time.
EQUES stated that it will proceed with the verification steadily and carefully based on the insights gained through this project. The company commented that it will strive to create new value by integrating its expertise from its "Pharma Document Generation AI SaaS" and "LLM Research Specializing in Pharmaceutical Operations" with AMED's knowledge. EQUES intends to continue contributing to the enhancement of Japan's drug discovery capabilities and the acceleration of R&D through cutting-edge generative AI technology and appropriate operational consulting.
In recent years, as interest in the use of digital technology in government agencies has grown, careful consideration is being given to the application of AI for improving operational efficiency and supporting decision-making, while addressing security and operational challenges. AMED has also been planning a phased examination of the potential for AI use in its internal operations.
This project is part of an initiative to enhance the operational efficiency of "Exit-oriented R&D Management," as stated in AMED's 3rd Mid-to-long-term Plan. The goal is to contribute to strengthening Japan's drug discovery capabilities by using generative AI to effectively utilize the drug discovery knowledge and project information accumulated within AMED, thereby accelerating the commercialization of promising drug discovery seeds.
The project will be conducted as a trial to perform technical and operational verification prior to a full-scale implementation of the AI platform. Through limited and non-public trial operations using AMED's accumulated drug discovery knowledge and project information, the following aspects will be verified:
- Assessment of the applicability of generative AI technology.
- Identification of technical and operational challenges for internal use.
- Confirmation of compliance with security and governance.
This initiative is in the verification phase, and the content of its results and future developments are not determined at this time.
EQUES stated that it will proceed with the verification steadily and carefully based on the insights gained through this project. The company commented that it will strive to create new value by integrating its expertise from its "Pharma Document Generation AI SaaS" and "LLM Research Specializing in Pharmaceutical Operations" with AMED's knowledge. EQUES intends to continue contributing to the enhancement of Japan's drug discovery capabilities and the acceleration of R&D through cutting-edge generative AI technology and appropriate operational consulting.